Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
about
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.Management of hepatocellular carcinoma: Enlightening the gray zones.Sorafenib in liver cancer.Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours.The effect of sorafenib on liver regeneration and angiogenesis after partial hepatectomy in rats.Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation.
P2860
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Sorafenib therapy for hepatoce ...... omplications after transplant.
@ast
Sorafenib therapy for hepatoce ...... omplications after transplant.
@en
type
label
Sorafenib therapy for hepatoce ...... omplications after transplant.
@ast
Sorafenib therapy for hepatoce ...... omplications after transplant.
@en
prefLabel
Sorafenib therapy for hepatoce ...... omplications after transplant.
@ast
Sorafenib therapy for hepatoce ...... omplications after transplant.
@en
P2093
P2860
P1476
Sorafenib therapy for hepatoce ...... omplications after transplant.
@en
P2093
Abdullah M S Al-Osaimi
Aimee E Truesdale
Curtis K Argo
Neeral L Shah
Patrick G Northup
Stephen H Caldwell
Timothy M Schmitt
P2860
P304
P356
10.1111/J.1432-2277.2011.01299.X
P577
2011-07-21T00:00:00Z